The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation

Journal of Autoimmunity

Volumn 58, Issue , 2015, Pages 12-20

  Rissiek, Anne ^a   Baumann, Isabell ^a   Cuapio, Angelica ^a   Mautner, Andrea ^a   Kolster, Manuela ^a   Arck, Petra C ^a   Dodge Khatami, Ali ^a,b   Mittrücker, Hans Willi ^a   Koch Nolte, Friedrich ^a   Haag, Friedrich ^a   Tolosa, Eva ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

CD39; IFN ; IL 17; Regulatory T cells; Single nucleotide polymorphism; Suppression

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BETA,GAMMA DIBROMOMETHYLENE 6 N,N DIETHYLADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3; APYRASE; LEUKOCYTE ANTIGEN;

ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; EFFECTOR CELL; GENOTYPE; HUMAN; HUMAN CELL; INFLAMMATION; INTRON; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; STABLE EXPRESSION; STIMULATION; THYMOCYTE; UPREGULATION; CELL CULTURE; CELL PROLIFERATION; CHILD; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; SYNOVIAL FLUID; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD; APYRASE; ARTHRITIS, JUVENILE; CELL PROLIFERATION; CELLS, CULTURED; CHILD; GENOTYPE; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SYNOVIAL FLUID; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 84930383519     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.12.007     Document Type: Article

References (32)

1. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
2. Baecher-Allan C., Wolf E., Hafler D.A. MHC class II expression identifies functionally distinct human regulatory T cells. JImmunol 2006, 176:4622-4631.
3. Kleinewietfeld M. CCR6 expression defines regulatory effector/memory-like cells within the CD25+CD4+ T-cell subset. Blood 2005, 105:2877-2886.
4. Thornton A.M., Korty P.E., Tran D.Q., Wohlfert E.A., Murray P.E., Belkaid Y., et al. Expression of helios, an ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. JImmunol 2010, 184:3433-3441.
5. Wang R., Kozhaya L., Mercer F., Khaitan A., Fujii H., Unutmaz D. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci 2009, 106:13439-13444.
6. Pesenacker A.M., Bending D., Ursu S., Wu Q., Nistala K., Wedderburn L.R. CD161 defines the subset of FoxP3+ T cells capable of producing proinflammatory cytokines. Blood 2013, 121:2647-2658.
7. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. JExp Med 2007, 204:1257-1265.
8. Friedman D.J., Künzli B.M., A-Rahim Y.I., Sévigny J., Berberat P.O., Enjyoji K., et al. From the cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A 2009, 106:16788-16793.
9. Borsellino G., Kleinewietfeld M., Di Mitri D., Sternjak A., Diamantini A., Giometto R., et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
10. Dwyer K.M., Deaglio S., Gao W., Friedman D., Strom T.B., Robson S.C. CD39 and control of cellular immune responses. Purinergic Signal 2007, 3:171-180.
11. Mandapathil M., Hilldorfer B., Szczepanski M.J., Czystowska M., Szajnik M., Ren J., et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. JBiol Chem 2010, 285:7176-7186.
12. Moncrieffe H., Nistala K., Kamhieh Y., Evans J., Eddaoudi A., Eaton S., et al. High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory t cell population. JImmunol 2010, 185:134-143.
13. Heuts D.P.H.M., Weissenborn M.J., Olkhov R.V., Shaw A.M., Gummadova J., Levy C., et al. Crystal structure of a soluble form of human CD73 with ecto-5'-nucleotidase activity. Chembiochem 2012, 13:2384-2391.
14. Fletcher J.M., Lonergan R., Costelloe L., Kinsella K., Moran B., O'Farrelly C., et al. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. JImmunol 2009, 183:7602-7610.
15. Herrath J., Chemin K., Albrecht I., Catrina A.I., Malmström V. Surface expression of CD39 identifies an enriched Treg-cell subset in the rheumatic joint, which does not suppress IL-17A secretion. Eur J Immunol 2014, 44:2979-2989.
16. Whiteside T.L. Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother 2012, 61:283-288.
17. Schulze Zur Wiesch J., Thomssen A., Hartjen P., Tóth I., Lehmann C., Meyer-Olson D., et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. JVirol 2011, 85:1287-1297.
18. Nikolova M., Carriere M., Jenabian M.-A., Limou S., Younas M., Kök A., et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 2011, 7:e1002110.
19. Atarashi K., Nishimura J., Shima T., Umesaki Y., Yamamoto M., Onoue M., et al. ATP drives lamina propria TH17 cell differentiation. Nature 2008, 455:808-812.
20. Purvis H.A., Anderson A.E., Young D.A., Isaacs J.D., Hilkens C.M.U. Anegative feedback loop mediated by STAT3 limits human Th17 responses. JImmunol 2014, 193:1142-1150.
21. Maliszewski C.R., Delespesse G.J., Schoenborn M.A., Armitage R.J., Fanslow W.C., Nakajima T., et al. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. JImmunol 1994, 153:3574-3583.
22. Kameoka J., Tanaka T., Nojima Y., Schlossman S.F., Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993, 261:466-469.
23. Dong R.P., Kameoka J., Hegen M., Tanaka T., Xu Y., Schlossman S.F., et al. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. JImmunol 1996, 156:1349-1355.
24. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., et al. Phenotypic and functional features of human Th17 cells. JExp Med 2007, 204:1849-1861.
25. Brucklacher-Waldert V., Stuerner K., Kolster M., Wolthausen J., Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
26. Brucklacher-Waldert V., Steinbach K., Lioznov M., Kolster M., Holscher C., Tolosa E. Phenotypical characterization of human Th17 cells unambiguously identified by surface IL-17A expression. JImmunol 2009, 183:5494-5501.
27. Reference SNP (refSNP) cluster report: rs10748643. this data is current as August 14th 2014. n.d. http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?searchType=adhoc_search%26type=rs%26rs=rs10748643.
28. Haskó G., Linden J., Cronstein B., Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008, 7:759-770.
29. Enjyoji K., Kotani K., Thukral C., Blumel B., Sun X., Wu Y., et al. Deletion of cd39/entpd1 results in hepatic insulin resistance. Diabetes 2008, 57:2311-2320.
30. Sauer A.V., Brigida I., Carriglio N., Aiut A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol 2012, 3:265.
31. Schrader W.P., West C.A., Miczek A.D., Norton E.K. Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction. JBiol Chem 1990, 265:19312-19318.
32. Rissiek A., Schulze C., Bacher U., Schieferdecker A., Thiele B., Jacholkowski A., et al. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia. Int J Cancer 2014, 135:2370-2379.